Which patents in the family
are actually worth challenging?
A branded drug is rarely covered by just one patent. We read the real Orange Book / FDA Paragraph IV listing for a drug and give you a structural, RDKit-verified read on every patent in that family: which ones are narrow and specific, which ones are broad and defensible. First-to-file exclusivity is worth real money; know where the real openings are before you commit to one.
The atoms are public. Who's asking isn't. We never publish client names, case details, or engagement records: anywhere, ever.
You give us the drug
A branded drug name, and what decision this supports: evaluating a Paragraph IV filing, or assessing challenge strength.
We read the whole family
The real Orange Book / FDA Paragraph IV listing for that drug, and the actual claimed chemistry in every patent in it: not a keyword scan.
You get a ranked read
Which patents look structurally narrow, which look genuinely broad. First-pass technical triage, not a legal opinion or a substitute for your own counsel's full diligence.
See a real screening
A completed, real two-patent family triage: including the exact kind of family-level nuance (which patent actually controls) a keyword search would miss.
Latest ANDA suits filed
New Hatch-Waxman ANDA cases (nature of suit 835) from public federal dockets, added as they are filed.
Covers a standard-sized patent family. If the family turns out unusually large (15+ patents), we'll follow up to confirm scope before starting the full read. This is technical triage on claimed chemistry, not a legal conclusion about validity or infringement: that judgment stays with you and your counsel.